Rejuvenation is a venture-backed pre-clinical stage biotechnology company out of Stanford University developing drugs to reverse aging. One dose of their lead compound, TERT mRNA, reverses 10+ years of telomere shortening, a major driver of aging and disease. Their goal is to extend everyone’s healthiest decades of life, and they are starting by treating fatal diseases of aging with high unmet medical need. TERT mRNA increases survival by >200%, prevents 68-95% of lung fibrosis, and increases lung function by 58% in the standard mouse model of idiopathic pulmonary fibrosis (IPF). In a liver fibrosis mouse model, TERT mRNA reduces liver fibrosis and inflammation, validating TERT mRNA as a platform technology with multiple clinical indications, each with a market size of $10B+.